<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: BACKGROUND - Multibacillary (MB) <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> may be manifested with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL), among which anti-beta2GP1 (beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> 1) </plain></SENT>
<SENT sid="1" pm="."><plain>High titers of aPL are associated with APS (<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid Syndrome</z:e>), characterized by <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The mutation Val247Leu in the domain V of beta2GP1 exposes hidden <z:chebi fb="0" ids="53000">epitopes</z:chebi> with consequent development of anti-beta2GP1 antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVE: To evaluate the Val247Leu polymorphism of beta2GP1 gene and its correlation with anti-beta2GP1 antibodies in <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The Val247Leu polymorphism was performed by PCR-RFLP and anti-beta2GP1 antibodies were measured by ELISA </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The genotypic Val/Val was more prevalent in the <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> group, compared to controls </plain></SENT>
<SENT sid="6" pm="."><plain>Regarding the 7 MB patients with APS, four presented heterozygosis and three, Val/Val homozygosis </plain></SENT>
<SENT sid="7" pm="."><plain>Although higher titrations of anti-beta2GP1 IgM antibodies were seen in <z:e sem="disease" ids="C1562585" disease_type="Disease or Syndrome" abbrv="">MB leprosy</z:e> group with Val/Leu and Val/Val genotypes, there was no statistical difference when compared to Leu/Leu genotype </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The prevalence of Val/Val homozygosis in <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> group can partially justify the presence of anti-beta2GP1 IgM antibodies in <z:e sem="disease" ids="C1562585" disease_type="Disease or Syndrome" abbrv="">MB leprosy</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The description of heterozygosis and Val/Val homozygosis in 7 patients with <z:e sem="disease" ids="C1562585" disease_type="Disease or Syndrome" abbrv="">MB leprosy</z:e> and <z:mp ids='MP_0005048'>thrombosis</z:mp> corroborates the implication of anomalous phenotype expression of beta2GP1 and development of anti-beta2GP1 antibodies, with consequent <z:mp ids='MP_0005048'>thrombosis</z:mp> and APS </plain></SENT>
</text></document>